Skip to content

Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company designing combination therapies for cancer.

Last updated September 11, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Arcus Biosciences is a clinical-stage, global biopharmaceutical company founded in 2015 with the goal of developing best-in-class molecules and combination therapies for people with cancer. It describes itself as being at the forefront of designing combination therapies, with discovery capabilities producing differentiated small molecules and antibodies designed to optimize combinability, and accelerated development guided by specific biologic mechanisms of cancer.

History

Arcus Biosciences was founded in 2015. Terry Rosen, PhD, and Juan Jaen, PhD, co-founded Arcus in 2015 as a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. The company describes itself as a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer.

Products and positioning

At the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer.

Sources6 sources

Cite this profile: Cite the canonical profile. /brand-wiki/arcus-biosciences · Editorial policy · How profiles are compiled